Back to Authors

Bansal, Shruti

Mayo Clinic

Columbia University Irving Medical Center

Citations 1

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
Ager, Casey R. , Zhang, Mingxuan , Chaimowitz, Matthew G., Bansal, Shruti, Tagore, Somnath, Jugler, Collin , Rogava, Meri , McCann, Patrick J. , Spina, Catherine, Drake, Charles G. , Izar, Benjamin , Izar, Benjamin , Tagore, Somnath , Obradović, Aleksandar , Melms, Johannes C. , McCann, Patrick, Dallos, Matthew C.

Journal for ImmunoTherapy of Cancer | September 1, 2023 | Volume: 11 | Issue: 9 | Pages: e006782

10.1136/jitc-2023-006782 Get It

Current methods for biomarker discovery and target identification in immuno-oncology rely on static snapshots of tumor immunity. To thoroughly characterize the temporal nature of antitumor immune responses, we developed a 34-parameter spectral flow cytometry panel and performed high-throughput analyses in critical contexts. We leveraged two distinct preclinical models that recapitulate cancer immunoediting (NPK-C1) and immune checkpoint blockade (ICB) response (MC38), respectively, and profiled multiple relevant tissues at and around key inflection points of immune surveillance and escape and/or ICB response. Machine learning-driven data analysis revealed a pattern of KLRG1 expression that uniquely identified intratumoral effector CD4 T cell populations that constitutively associate with tumor burden across tumor models, and are lost in tumors undergoing regression in response to ICB. Similarly, a Helios-KLRG1+ subset of tumor-infiltrating regulatory T cells was associated with tumor progression from immune equilibrium to escape and was also lost in tumors responding to ICB. Validation studies confirmed KLRG1 signatures in human tumor-infiltrating CD4 T cells associate with disease progression in renal cancer. These findings nominate KLRG1+ CD4 T cell populations as subsets for further investigation in cancer immunity and demonstrate the utility of longitudinal spectral flow profiling as an engine of dynamic biomarker discovery.